Tango Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Collaboration revenue | $31,527 | $24,860 |
| License revenue | 5,000 | — |
| Total revenue | 36,527 | 24,860 |
| Operating expenses: | ||
| Research and development | 115,198 | 105,906 |
| General and administrative | 35,502 | 30,025 |
| Total operating expenses | 150,700 | 135,931 |
| Loss from operations | (114,173) | (111,071) |
| Other income: | ||
| Interest income | 6,619 | 1,456 |
| Other income, net | 5,944 | 1,493 |
| Total other income, net | 12,563 | 2,949 |
| Loss before income taxes | (101,610) | (108,122) |
| Provision for income taxes | (134) | (54) |
| Net loss | $(101,744) | $(108,176) |
| Net loss per common share – basic and diluted | $(1.08) | $(1.23) |
| Weighted average number of common shares outstanding – basic and diluted | 94,572,448 | 87,820,037 |
| Net loss | $(101,744) | $(108,176) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on marketable securities | 3,891 | (2,940) |
| Comprehensive loss | $(97,853) | $(111,116) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.